TQ Quiz | Understanding Glaucoma: Pathology, Diagnosis & Treatment (Orlando 2024) by Events@optometricedu.com | Jun 10, 2024 | TQ Courses | 0 comments "*" indicates required fields Hidden@{:35}HiddenDate (Hidden) MM slash DD slash YYYY HiddenEvent Date (Hidden) MM slash DD slash YYYY HiddenEvent 60 days past date (Hidden) MM slash DD slash YYYY HiddenEvent Date Difference (Hidden)1. All of the following are mechanisms associated with the development of open angle glaucoma except:* A - Mechanical B - Vascular C - Genetic D - Neurophrenetic 2. Glaucoma is a disease on the continuum of:* A - Ischemic optic neuropathy B - Infectious disease C - Autoimmune / inflammatory disease D - Both A and C 3. All are signs of potential glaucomatous disease except:* A - Cupping B - Increased IOP C - Family history D - Visual field loss 4. All are risk factors associated with glaucomatous disease except:* A - High IOP B - Family history of glaucoma C - History of migraine headache. D - History of systemic infection 5. The glaucomatous work up includes all of the following except:* A - Visual fields B - Tonometry C - ESR D - Nerve fiber layer analysis 6. Glaucoma diagnosis depends on:* A - Correlation of repeatable, reliable findings. B - One suspicious field C - IOP above 24 mmHg D - Cupping of .5 or more 7. All of the following make gonioscopy important except:* A - Pigment dispersion B - Bullous keratopathy C - Angle recession D - PAS 8. To rule out synechial closure as opposed to pupil block, this technique should be employed:* A - Treacher breach B - Peripheral haulter C - Forbe’s compression D - Radial steal 9. Visual fields measure:* A - The light – wave ERG B - Periodic visual cycle C - Functional visual limits D - Structural losses 10. GDX and HRT evaluations measure:* A - Structural integrity B - Functional losses C - Cup – mass ratio D - Genetic risk 11. Xalatan is an example of a:* A - Prostaglandin class medicine B - A beta blocker class medicine C - Sympathomimetic class medicine D - A parasympathomimetic medicine 12. A significant problem for many patients placed on topical glaucoma medications is:* A - Lost color vision B - Anxiety C - Noncompliance D - Loss of memory 13. The CNTG study recommended:* A - Lower IOP by at least 30 % for maximum effect B - IOP lowering is ineffective C - Blacks require surgery while whites require peripheral iridotomy D - Filtering should be considered before topical medications 14. The OHTS demonstrated* A - Laser is as effective as drops B - Elevated IOP and thinner corneal thickness are two significant risk factors C - Gonioplasty should be considered last D - IOP does not matter 15. The AGIS demonstrated:* A - Consistent IOP lowering below 18 mmHg provides the most risk reduction B - Lowering IOP in blacks is ineffective C - Lowering IOP in whites should be done with surgery first D - IOP is not a risk factor 16. The EMGT demonstrated* A - IOP does matter B - Laser is more effective than drops C - Prostaglandins should be used first D - The genetic mechanism of glaucoma 17. Reevaluation of the glaucoma patient should include all of the following except* A - IOP measurement B - Visual field evaluation C - Repeat analysis of the nerve fiber layer D - All of the above should be included 18. Pachymetry has recently become important because* A - Corneal thickness is billable B - AGIS demonstrated a relationship to pupil block C - OHTS demonstrated a potential correlation of risk to thickness D - It alters IOP by impeding aqueous egress 19. All of the following are examples of open angle glaucomas except:* A - Pigmentary B - Pseudoexfoliative C - Posner – Schlossmann D - Pupil block 20. Posner Schlossmann syndrome is considered:* A - A trebeculitis B - A viral episode C - A form of intermittent angle closure D - A varient of neovascular glaucoma Personal InformationName* First Last Email* Phone*OE Tracker # License # Address* Street Address Address Line 2 City State / Province / Region ZIP / Postal Code AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussian FederationRwandaRéunionSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTaiwanTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkmenistanTurks and Caicos IslandsTuvaluTürkiyeUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Country Payment InformationPromotional Code Disney 2024 - Understanding Glaucoma: Pathology, Diagnosis & Treatment | TQ Credit*After 8/8/2024, pricing will increase to $30. Price: (Past 60 Days) Disney 2024 - Understanding Glaucoma: Pathology, Diagnosis & Treatment | TQ CreditThis course was presented over 60 days ago. Due to this late submission of TQ, your TQ credit price is $30. Price: Retake Discount Price: Promotional Discount Price: (Past 60 Days) Retake Discount Price: (Past 60 Days) Promotional Discount Price: Credit Card* HiddenCourse Information (HIDDEN)HiddenCourse Name (HIDDEN) HiddenRetake Code (HIDDEN) HiddenQuiz URL (HIDDEN)Do not include ending backslash (aka no .com/) HiddenCE Hours Submit a Comment Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website
